related documents
- A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma Conferences
- Difficulties in meeting accrual and obtaining adequate follow up in palliative trials: Results from an intergroup randomized trial of single vs multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20 Conferences
- Genomic testing in cancer (GTC): Patient knowledge, attitudes and expectations Conferences
- Homecare utilization and costs in stage IV lung cancer: a Canadian public payer experience Conferences
- Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy Conferences